SUBSCRIBE
SUBSCRIBE

Crossbow Therapeutics

NEWS
Map of NextGen Class of 2024/BioSpace
Business
NextGen Class of 2024: Top Life Sciences Startups to Watch This Year
Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months.
January 3, 2024
 · 
20 min read
 · 
BioSpace Editorial Staff
IN THE PRESS
Press Releases
Crossbow Therapeutics Nominates its Second Development Candidate, CBX-663, a Broadly Acting Therapeutic for a Wide Range of Solid and Hematologic Malignancies
July 24, 2025
 · 
3 min read
Genetown
Crossbow Therapeutics Selects First Development Candidate from its Portfolio of Next-Generation T-cell Engagers Directed at Intracellular Cancer Targets
March 5, 2024
 · 
4 min read
AWARDS
  • NextGen Badge - Brighspot Rework_NextGen - Class of 2024.jpg
JOBS